Mr. M

DON’T SPAM DURING MKT HOURS

[Coin Bureau @coinbureau]

🚨SHOCKING: POLYMARKET PAID CREATORS TO STAGE $1.9 MILLION IN FAKE BETS

A WSJ investigation reviewed 1,105 videos posted by Polymarket creators and found that NONE of the bets were real.

Creators were filming trades on FAKE copies of the Polymarket website and getting paid $2,000 to $3,000 a month to post them.

The same bets they showed as wins would have actually LOST over $166,000.

Polymarket says it will now audit its promotional content.

[Elon Musk @elonmusk]

Case closed

[MoundLore @MoundLore]

Florida LiDAR

[unusual_whales @unusual_whales]

Yum Brands to sell Pizza Hut for $2.7 billion

[Cheddar Flow @CheddarFlow]

When oil tycoon John D. Rockefeller's fortune was at its peak, his net worth was equal to about 1.5% of U.S. gross domestic product

Elon Musk's net worth is now equivalent to more than 3% of U.S. GDP, per NYT

[Dr. Maalouf ‏ @realMaalouf]

In Yemen, 90% of men and 50% of women chew khat daily. A quarter of all their household income is spent on this plant.

Alcohol is haram, but they are all drug addicts. Make it make sense.

[Elon Musk @elonmusk]

Next I’m buying Coca-Cola to put the cocaine back in

[Mr. M @RubleSmuggler]

@rgvitanza @StockSavvyShay Unless it’s $SMMT. Insiders bought $100M shares Friday. It’s still on discount too. ;)

[Mr. M @RubleSmuggler]

@DennRoe @StockSavvyShay Fucking PayPal haha. Now watch it 3x..

[Mr. M @RubleSmuggler]

@DennRoe @StockSavvyShay Lmao yes

[Seth @Notbullnorbear]

Happy Friday

[Mr. M @RubleSmuggler]

@Glitch_Trades Smart for all of those people asking a thousand questions

[Mr. M @RubleSmuggler]

@Glitch_Trades Burn it

[Mr. M @RubleSmuggler]

@Glitch_Trades Webull is working great

[Data Driven Stocks @stockdatamarket]

Bears - don't short the rally please!

If you really want, short it 30 minutes before the close.

Now $SPX is gamma pinned for the rest of the day.

[Mr. M @RubleSmuggler]

@A_Najumi I get super stressed when things are going well

[Mr. M @RubleSmuggler]

@vandy_trades

[Mr. M @RubleSmuggler]

@kastriooot8 What do you know 👀

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson